Sponsor: Novartis
Protocol Number: CVAY736A2302
|
A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjögren's syndrome (NEPTUNUS-2) |
Detailed Information: Here
To learn more or see if you qualify: Click Here
/assets/production/practices/c1f0c98a14a26efc3f61c530443c39569f27073b/images/2610812.jpg)